Related Experiment Video

Updated: Jun 12, 2026

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
09:37

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Published on: December 2, 2014

STEMI and heart failure in the elderly: role of adverse remodeling

Anwar Jelani1, Bodh I Jugdutt

  • 12C2 Walter MacKenzie Health Sciences Centre, Division of Cardiology, Department of Medicine and Cardiovascular Research Group, Faculty of Medicine, University of Alberta Hospital, Edmonton, AB T6G 2R7, Canada.

Heart Failure Reviews
|June 16, 2010
PubMed

Insights

Elderly individuals face higher risks of heart failure (HF) and ST-segment elevation myocardial infarction (STEMI). More research is crucial to improve HF and STEMI treatments in older adults.

Area of Science:

  • Cardiology
  • Gerontology
  • Biomedical Science

Background:

  • The global elderly population is growing, with increased prevalence of heart failure (HF) and ST-segment elevation myocardial infarction (STEMI) in North America and Europe.
  • Elderly patients experience higher morbidity, hospitalization rates, and healthcare costs associated with HF.
  • Cardiovascular deaths disproportionately affect the elderly, even with advancements in treatment.

Purpose of the Study:

  • To highlight the challenges and knowledge gaps in managing adverse ventricular remodeling post-STEMI and HF in the elderly.
  • To emphasize the need for dedicated research on the impact of aging on cardiac remodeling and HF progression.
  • To advocate for more clinical trials focusing on elderly populations, particularly the "older-elderly" (≥75 years).

Main Methods:

  • Review of existing literature on HF and STEMI in the elderly.
  • Analysis of age-specific biological changes, comorbidities, and polypharmacy impacting HF treatment.
  • Identification of gaps in clinical trial data for elderly patients with HF and post-STEMI remodeling.

Main Results:

  • Limited clinical trial data exists for elderly patients regarding specific therapies for adverse remodeling post-STEMI and HF (both HF with low ejection fraction and HF with preserved ejection fraction).
  • The impact of aging on ventricular remodeling during the healing process after STEMI and in HF remains understudied.
  • HF management in the elderly is complicated by age-related biological changes, comorbidities, and polypharmacy.

Conclusions:

  • There is a critical need for more research into aging and post-STEMI remodeling.
  • Clinical trials specifically designed for elderly populations, especially those aged 75 and above, are essential for advancing HF and post-STEMI care.
  • Addressing the unique challenges of HF in the elderly is paramount for reducing cardiovascular mortality and morbidity.

More Related Videos

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...